The use of systemic treatment in the maintenance of patients with non-small cell lung cancer: A systematic review

Journal of Thoracic Oncology

Volumn 11, Issue 7, 2016, Pages 989-1002

  Kulkarni, Swati ^a   Vella, Emily T ^b   Coakley, Nadia ^b   Cheng, Susanna ^c   Gregg, Richard ^d   Ung, Yee C ^c   Ellis, Peter M ^b,e  

^a Medical Oncology   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d Medical Oncology   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Chemotherapy; Epidermal growth factor receptor tyrosine kinase inhibitors; Maintenance systemic therapy; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; TAXOID;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; COUGHING; DIARRHEA; DYSPNEA; FATIGUE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MEDICAL DECISION MAKING; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PEMETREXED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 84978194385     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.03.007     Document Type: Review

References (36)

1. National Cancer Institute of Canada. Canadian cancer statistics 2001. (Internet). http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statisticspublication/?region=on. Accessed December 20, 2015.
2. Sun J-M, Park JO, Won Y-W, et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol. 2010;5:540-545.
3. Gerber DE, Rasco DW, Le P, et al. Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol. 2011;6:365-371.
4. Kulkarni S, Vella, E, Coakley N, et al. The use of systemic treatment in the maintenance of patients with non-small cell lung cancer. Toronto, ON: Cancer Care Ontario; Program in Evidence-Based Care Evidence-Based Series; No. 7-22. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=345529. Accessed December 17, 2015.
5. Review Manager (RevMan) [computer program]. Version 4.2 for Windows. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2003.
6. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints [erratum appears in Stat Med. 2004;23:1817] Stat Med. 1998;17:2815-2834.
7. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-394.
8. Brozek J, Nowak A, Kunstman P, et al. GRADEpro Guideline Development Tool (G2DT) [computer program]: (Computer Program) Version 2. www.guidelinedevelopment.org); 2014. Accessed July 7, 2014.
9. Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516-3524.
10. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; CTONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012;13:466-475.
11. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247-255.
12. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer [erratum appears in J Clin Oncol. 2011;29: 4725] J Clin Oncol. 2011;29:4113-4120.
13. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-529.
14. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
15. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52:155-163.
16. Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2010;28(suppl 15):7506.
17. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:591-598.
18. Zinner R, Ross HJ, Weaver R, et al. Randomized, openlabel, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2013;31(suppl):LKBA8003.
19. Zhang L, Lu S, Cheng Y, et al. Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, CTONG 0904) [abstract]. J Clin Oncol. 2013;31(suppl): 8015.
20. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:4349-4357.
21. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-smallcell lung cancer. J Clin Oncol. 2013;31:3926-3934.
22. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895-2902.
23. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31:3004-3011.
24. Rittmeyer A, Gorbunova V, Vikstrom A, et al. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol. 2013;8:1409-1416.
25. Nagy A, Fouad E, Nasr K, et al. Maintenance low-dose gemcitabine versus best supportive care in advanced and metastatic non-small cell lung cancer: randomized phase III trial. J Thorac Oncol. 2014;9(suppl 9):S46.
26. Lu S, Zhang L, Wu YL, et al. Overall survival analysis results of TFINE study (ctong 0904): different dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single agent docetaxel for advanced non-small cell lung cancer. J Thorac Oncol. 2013;8:S1177.
27. Obasaju C, Bowman L, Wang P, et al. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). Ann Oncol. 2013;24:1534-1542.
28. Reck M, Paz-Ares LG, de Marinis F, et al. PARAMOUNT: descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2014;9:205-213.
29. Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol. 2012;23:388-394.
30. Belani CP, Wu Y-L, Chen Y-M, et al. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol. 2012;7:567-573.
31. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14: 253-263.
32. Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol. 2012;19:e9-e15.
33. Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC; Lung Disease Site Group. Use of the epidermal growth factor receptor inhibitors gefitinib (Iressa®), erlotinib (Tarceva ®), afatinib, dacomitinib or icotinib in the treatment of non-small-cell lung cancer: a clinical practice guideline. Toronto, ON: Cancer Care Ontario; Program in Evidence-Based Care Evidence-Based Series No. 7-9 Version 2. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34353. Accessed September 25, 2014.
34. Government of Canada website. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/56720a-eng.php. Accessed March 3, 2016.
35. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01328951. Accessed March 3, 2016.
36. Cai H, Lin Y, Li W, et al. Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2013;14:333-341.